ScripGrifols, S.A. is the latest biopharma company forced to cut its cloth to suit the straitened times the sector is suffering, with the Spanish plasma powerhouse unveiling plans to axe 8% of its workfor
ScripEven with less venture capital raised during the first quarter of 2022 than in Q1 of 2021, VC financing has become the most common type of financing for biopharmaceutical firms raising cash in 2022, a